ketoconazole has been researched along with Disease Exacerbation in 19 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In contrast, in four patients with polycystic kidney disease, progression accelerated by 99% +/- 63%." | 2.68 | Effect of ketoconazole plus low-dose prednisone on progression of chronic renal failure. ( Hill, S; Walser, M, 1997) |
| "In a large proportion of advanced prostate cancer patients treated with androgen deprivation therapy, progression of the disease occurs despite low levels of testosterone, termed castration-resistant prostate cancer." | 2.45 | Novel secondary hormonal therapy in advanced prostate cancer: an update. ( Ryan, CJ; Van Allen, EM, 2009) |
| "Ketoconazole is a well-known CYP17-targeted systemic treatment for castration-resistant prostate cancer (CRPC)." | 1.42 | Prospective evaluation of low-dose ketoconazole plus hydrocortisone in docetaxel pre-treated castration-resistant prostate cancer patients. ( Beckett, LA; Lara, PN; Lo, EN; Pan, CX; Robles, D; Sands, JM; Suga, JM, 2015) |
| "Ketoconazole has moderate activity as secondary hormonal therapy in patients with CRPC previously treated with taxane-based chemotherapy, although the TTP was short." | 1.36 | Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer. ( Jacobus, S; Kantoff, PW; Nakabayashi, M; Oh, WK; Regan, MM; Rosenberg, JE; Taplin, ME, 2010) |
| "In castration-resistant prostate cancer (CRPC) many androgen-regulated genes become re-expressed and tissue androgen levels increase despite low serum levels." | 1.35 | Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts. ( Adomat, HH; Gleave, ME; Guns, ES; Hendy, SC; Locke, JA; Nelson, CC, 2009) |
| "Ketoconazole is a commonly used secondary hormonal therapy in castration-refractory prostate cancer (CRPC), but disease progression inevitably occurs." | 1.35 | Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone. ( Balk, SP; Kantoff, PW; Nakabayashi, M; Oh, WK; Ross, RW; Sartor, O; Taplin, ME, 2009) |
| "The median time to disease progression or dose escalation on LDK was 3." | 1.33 | Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer. ( Jackman, DM; Kantoff, PW; Nakabayashi, M; Oh, WK; Regan, MM; Xie, W, 2006) |
| "at bedtime)." | 1.31 | Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. ( Bok, RA; Harris, KA; Kakefuda, M; Small, EJ; Weinberg, V, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (10.53) | 18.2507 |
| 2000's | 8 (42.11) | 29.6817 |
| 2010's | 9 (47.37) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Biagetti, B | 1 |
| Simó-Servat, O | 1 |
| Ortiz-Z, A | 1 |
| Iglesias, C | 1 |
| Mesa, J | 1 |
| Aggarwal, R | 1 |
| Halabi, S | 1 |
| Kelly, WK | 1 |
| George, D | 1 |
| Mahoney, JF | 1 |
| Millard, F | 1 |
| Stadler, WM | 1 |
| Morris, MJ | 1 |
| Kantoff, P | 1 |
| Monk, JP | 1 |
| Carducci, M | 1 |
| Small, EJ | 3 |
| Peer, A | 1 |
| Gottfried, M | 1 |
| Sinibaldi, V | 1 |
| Carducci, MA | 2 |
| Eisenberger, MA | 2 |
| Sella, A | 1 |
| Leibowitz-Amit, R | 1 |
| Berger, R | 1 |
| Keizman, D | 2 |
| Lo, EN | 1 |
| Beckett, LA | 1 |
| Pan, CX | 1 |
| Robles, D | 1 |
| Suga, JM | 1 |
| Sands, JM | 1 |
| Lara, PN | 1 |
| Paun, DL | 1 |
| Vija, L | 1 |
| Stan, E | 1 |
| Banica, A | 1 |
| Bobeica, E | 1 |
| Terzea, D | 1 |
| Poiana, C | 1 |
| Badiu, C | 1 |
| Paun, S | 1 |
| Davis, JP | 1 |
| Salmon, M | 1 |
| Pope, NH | 1 |
| Lu, G | 1 |
| Su, G | 1 |
| Meher, A | 1 |
| Ailawadi, G | 1 |
| Upchurch, GR | 1 |
| Sedhom, R | 1 |
| Hu, S | 1 |
| Ohri, A | 1 |
| Infantino, D | 1 |
| Lubitz, S | 1 |
| Van Allen, EM | 1 |
| Ryan, CJ | 1 |
| Locke, JA | 1 |
| Nelson, CC | 1 |
| Adomat, HH | 1 |
| Hendy, SC | 1 |
| Gleave, ME | 1 |
| Guns, ES | 1 |
| Sartor, O | 1 |
| Nakabayashi, M | 3 |
| Taplin, ME | 2 |
| Ross, RW | 1 |
| Kantoff, PW | 3 |
| Balk, SP | 1 |
| Oh, WK | 3 |
| Jacobus, S | 1 |
| Regan, MM | 2 |
| Rosenberg, JE | 1 |
| Huang, P | 1 |
| Harris, KA | 1 |
| Weinberg, V | 1 |
| Bok, RA | 1 |
| Kakefuda, M | 1 |
| Argirovic, Dj | 1 |
| Xie, W | 1 |
| Jackman, DM | 1 |
| Oosterhuis, JK | 1 |
| van den Berg, G | 1 |
| Monteban-Kooistra, WE | 1 |
| Ligtenberg, JJ | 1 |
| Tulleken, JE | 1 |
| Meertens, JH | 1 |
| Zijlstra, JG | 1 |
| Walser, M | 1 |
| Hill, S | 1 |
| Baron, AD | 1 |
| Fippin, L | 1 |
| Apodaca, D | 1 |
| Nijhawan, M | 1 |
| Nijhawan, S | 1 |
| Vijayvergiya, R | 1 |
| Agarwal, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Assessing PSA Response in Low Dose Ketoconazole in Hormone Refractory Prostate Cancer Patients Who Have Failed at Least One Prior Systemic Chemotherapy Regimen[NCT00895310] | Phase 2 | 30 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Mechanisms of Control of the Intratesticular Hormonal Milieu in Man[NCT01215292] | Phase 1/Phase 2 | 46 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00895310)
Timeframe: From date of enrollment, every Cycle (4 weeks), until disease progression, unacceptable toxicities, study withdrawal, or death from any cause, whichever came first, assessed up to 2 years
| Intervention | Days (Median) |
|---|---|
| Ketoconazole | 123 |
Response Evaluation Criteria In Solid Tumors (RECIST) radiographic criteria for progression (NCT00895310)
Timeframe: From date of enrollment, every Cycle (4 weeks), until disease progression, unacceptable toxicities, study withdrawal, or death from any cause, whichever came first, assessed up to 2 years
| Intervention | Days (Median) |
|---|---|
| Ketoconazole | 138 |
Percentage of patients who achieved a clinically significant decline in Prostate Specific Antigen (PSA) after initiation of ketoconazole therapy, defined as a >=50% decrease in PSA. (NCT00895310)
Timeframe: From date of enrollment, every Cycle (4 weeks), until disease progression, unacceptable toxicities, study withdrawal, or death from any cause, whichever came first, assessed up to 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Ketoconazole | 14 |
(NCT00895310)
Timeframe: From date of enrollment, every Cycle (4 weeks), until disease progression, unacceptable toxicities, study withdrawal, or death from any cause, whichever came first, assessed up to 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Ketoconazole | 17 |
(NCT01215292)
Timeframe: 10 days
| Intervention | ng/mL (Median) |
|---|---|
| Acyline + Testosterone Gel (Tgel)+ Placebo | .87 |
| Acyline + Tgel + Ketoconazole 400mg | 0.5 |
| Acyline + Tgel + Ketoconazole 800mg | 0.12 |
| Acyline & TGel & Dutasteride 2.5mg | 1.7 |
| Acyline & TGel & Anastrazole 1mg | 3.6 |
(NCT01215292)
Timeframe: 10 days
| Intervention | ng/mL (Median) |
|---|---|
| Acyline + Testosterone Gel (Tgel)+ Placebo | 3.17 |
| Acyline & TGel & Ketoconazole 400 mg | 2.08 |
| Acyline & TGel & Ketoconazole 800 mg | 1.46 |
| Acyline & TGel & Dutasteride | 0.12 |
| Acyline & TGel & Anastrazole | 3.63 |
(NCT01215292)
Timeframe: 10 days
| Intervention | ng/mL (Median) |
|---|---|
| Acyline + Testosterone Gel + Placebo | 14 |
| Acyline + Tgel + Ketoconazole 400mg | 3.7 |
| Acyline + Tgel + Ketoconazole 800mg | 1.7 |
| Acyline & TGel & Dutasteride 2.5mg | 18.4 |
| Acyline & TGel & Anastrazole 1mg | 24.0 |
1 review available for ketoconazole and Disease Exacerbation
| Article | Year |
|---|---|
Novel secondary hormonal therapy in advanced prostate cancer: an update.
Topics: Androgen Antagonists; Androstenes; Androstenols; Disease Progression; Humans; Ketoconazole; Male; Pr | 2009 |
3 trials available for ketoconazole and Disease Exacerbation
| Article | Year |
|---|---|
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (
Topics: Aged; Androgen Antagonists; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antineoplastic Com | 2013 |
Effect of ketoconazole plus low-dose prednisone on progression of chronic renal failure.
Topics: Adrenocorticotropic Hormone; Adult; Aged; Aged, 80 and over; Cross-Over Studies; Diabetic Nephropath | 1997 |
Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Disease Progression; Flutamide; Humans; Hy | 1997 |
15 other studies available for ketoconazole and Disease Exacerbation
| Article | Year |
|---|---|
Ectopic Cushing's syndrome: Paradoxical effect of somatostatin analogs.
Topics: ACTH Syndrome, Ectopic; Adrenal Gland Neoplasms; Adrenal Medulla; Adrenalectomy; Adrenocorticotropic | 2017 |
Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Combined Modali | 2014 |
Prospective evaluation of low-dose ketoconazole plus hydrocortisone in docetaxel pre-treated castration-resistant prostate cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Diseas | 2015 |
Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion from a Meckel diverticulum neuroendocrine tumor: case report.
Topics: ACTH Syndrome, Ectopic; Adrenocorticotropic Hormone; Adult; Corticotropin-Releasing Hormone; Cushing | 2015 |
Pharmacologic blockade and genetic deletion of androgen receptor attenuates aortic aneurysm formation.
Topics: Androgen Antagonists; Animals; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Cytokines; Disease Mode | 2016 |
Symptomatic Cushing's syndrome and hyperandrogenemia in a steroid cell ovarian neoplasm: a case report.
Topics: Aged; Antineoplastic Agents, Hormonal; Cushing Syndrome; Disease Progression; Fatal Outcome; Female; | 2016 |
Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts.
Topics: Androgen Antagonists; Androgens; Anilides; Animals; Castration; Cell Line, Tumor; Cinnamates; Diseas | 2009 |
Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Azasteroids; | 2009 |
Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bridged-Ring Compounds; Castration; Dis | 2010 |
Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: clinical factors associated with PSA response and disease progression.
Topics: Adrenal Glands; Aged; Aged, 80 and over; Androgens; Cohort Studies; Disease Progression; Dose-Respon | 2012 |
Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Biomarkers, Tumor; Disease | 2002 |
An evaluation of high-doses ketoconazole with hydrocortisone substitution in hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Dis | 2005 |
Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Disease Progress | 2006 |
Life-threatening Pneumocystis jiroveci pneumonia following treatment of severe Cushing's syndrome.
Topics: Cushing Syndrome; Disease Progression; Fatal Outcome; Female; Humans; Ketoconazole; Middle Aged; Mif | 2007 |
Oral histoplasmosis.
Topics: Aged; Biopsy, Needle; Disease Progression; Fatal Outcome; Fungemia; Histoplasmosis; Humans; India; K | 2001 |